The global Anticoagulant Reversal Drugs Market, valued at US$ 829.5 million in 2021, is projected to grow at a compound annual growth rate (CAGR) of 11.3% from 2022 to 2031, reaching more than US$ 2.3 billion by 2031. Anticoagulant reversal drugs, such as idarucizumab and andexanet alfa, are used to reverse the effects of anticoagulants in cases of life-threatening bleeding or emergency...